Catherine J. Friedman has served as a member of our Board of Directors since March 2016. Ms. Friedman has been an independent financial consultant serving public and private companies in the life sciences industry since 2006. Prior to that, Ms. Friedman held numerous positions over a 23-year investment banking career with Morgan Stanley, including Managing Director from 1997 to 2006 and Head of West Coast Healthcare and Co-Head of the Biotechnology Practice from 1993 to 2006. Ms. Friedman is a member of the boards of directors of Lyell Immunopharma, a biopharmaceutical company focused on cell-based immunotherapies and Seer, Inc., a life sciences company that engages in developing nanoparticle technology solutions for researchers in the areas of proteomics information. She previously served as a member of the boards of directors of Grail Inc., a life sciences company focused on early cancer detection until 2021, Radius Health, Inc., a biopharmaceutical company from 2015 until 2022, Revolution Healthcare Acquisition Corp from 2021 until 2022, Vividion Therapeutics, Inc. a biotechnology company focused on the creation of highly selective small molecule medicines until 2021, Innoviva, Inc. (formerly Theravance, Inc.), a royalty management company, from June 2014 to April 2018, EnteroMedics Inc., a medical device company, from May 2007 to May 2016, XenoPort, Inc., a biopharmaceutical company, from September 2007 to July 2016, and GSV Capital Corp., a publicly traded business development company, from March 2013 to March 2017.